Company: ACBM
Filing Date: 2025-07-11
Form Type: 10-Q
Source: 0001640334-25-001169
Chunk: 17

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-11
Form: 10-Q
Item: Item 1
Chunk 17
---
 60,042,000   60,042,000   60,042,000 

The accompanying notes are an integral part of these unaudited financial statements.

 5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

(Unaudited)

For the Three and Nine months ended September 30, 2023

              Additional  Deferred     Total   Preferred Stock  Common Stock   Paid in   Stock  Accumulated  Stockholders'     Shares    Amount    Shares    Amount    Capital   Compensation   Deficit   Equity (Deficit)                          Balance, December 31, 2022  -  $-   60,042,000  $60,042  $32,295,236  $(8,060,983) $(23,807,925) $486,370                                  Amortization of deferred stock compensation   -   -   -   -   -   3,928,100   -   3,928,100 Imputed interest on related party loans  -   -   -   -   788   -   -   788 Net loss  -   -   -   -   -   -   (4,004,354)  (4,004,354)                                 Balance, March 31, 2023  -   -   60,042,000   60,042   32,296,024   (4,132,883)  (27,812,279)  410,904                                  Amortization of deferred stock compensation   -   -   -   -   -   3,123,450   -   3,123,450 Imputed interest on related party loans  -   -   -   -   789   -   -   789 Net loss  -   -   -   -   -   -   (3,195,489)  (3,195